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1. Introduction 
Several microorganisms take advantages of the most common single gene disorder afflicting 
Caucasians and colonize the airways of cystic fibrosis (CF) patients. Although CF is a multi-
system disorder, the associated mortality is mostly due to respiratory problems subsequent 
to chronic bacterial infections. CF is the result of mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) which is a cAMP-regulated chloride channel 
and a regulator of the activity of other channels. Consequently, there is a significant 
dehydration of the airway mucus when CFTR is dysfunctional. However, the exact reason 
why CF predisposes the lungs to microbial infections is not completely understood. It is 
thought that the obstruction of the airways by mucus and the proinflammatory status 
associated with this disease may be part of the explanation (Lyczak et al., 2002; Riordan, 
2008).  
The recalcitrance of CF pathogens to antibiotic therapies is a major problem and is 
responsible for most of the morbidity and the mortality associated with CF (Chmiel & Davis, 
2003; Lyczak et al., 2002). The ever-growing and overwhelming problems caused by 
antibiotic-resistant bacteria in human medicine have not spared CF patients. Antibiotic-
resistant bacteria are frequently recovered from CF samples (George et al., 2009; Parkins & 
Elborn, 2010). The evolution of drug resistance has been accelerated by the extensive use of 
an antibiotic arsenal which has become limited due to insufficient innovation in the 
development of antimicrobials (Shah, 2005; Talbot et al., 2006). Indeed, the development of 
new classes of antibiotics has been almost abandoned for the last four decades and 
antibiotics that were introduced during this period usually consisted of new-generation 
molecules derived from existing antibiotics (Wenzel et al., 2005). Furthermore, long-term 
infections of the CF airways not only allow pathogens to adapt and circumvent the host 
immune system, but also allow them time to adapt to antibiotic therapies (Goerke & Wolz, 
2010; Hogardt & Heesemann, 2010). Several mechanisms that decrease the susceptibility to 
antimicrobials are known to be at play in the CF airways. Conventional resistance 
mechanisms include the upregulation of bacterial efflux pumps and mutations of antibiotic 
target molecules (Høiby et al., 2010). In addition, the formation of persister cells (Mulcahy et 
al., 2010) and of small-colony variants (Goerke & Wolz, 2010; Proctor et al., 2006; Schneider et 
al., 2008) as well as bacterial growth in biofilms (Høiby et al., 2010; Mitchell et al., 2010a, 
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2010b; Wagner & Iglewski, 2008) are mechanisms that are well known for their involvement 
in difficult-to-treat infections (Galli et al., 2007; Stewart, 2002).  
The formation of bacterial biofilms may explain, at least in part, the failure of many 
antimicrobial therapies. Biofilm-growing bacteria are highly persistent in CF because they 
appear to be physically protected from the host immune system and are inherently resistant 
to antimicrobials (Costerton et al., 1999; Davies & Bilton, 2009; Høiby et al., 2010; Stewart, 
2002). These bacteria are thought to be as much as 1000 times more resistant to 
antimicrobials than their planktonic counterparts (George et al., 2009). Biofilms also 
represent complex integrated polymicrobial communities that are strongly influenced by 
cell-to-cell intraspecies and interspecies communications (Costerton et al., 1999; Hall-
Stoodley et al., 2004; Stoodley et al., 2002). The different species of microbes found in 
polymicrobial infections such as in CF most probably respond to each other’s chemical 
signals in order to survive and this is likely to influence the course of any particular 
infection (Brogden et al., 2005; Ryan & Dow, 2008). 
In the surge to develop new therapies against CF pathogens, multiple aspects should be 
considered. Indeed, several diverse phenotypic adaptations confer a selective advantage in 
the host environment or toward antibiotic therapies. Also to consider are the various 
bacterial signals used for cell-to-cell communication that are involved in the establishment 
and the development of an infection. These mechanisms enable pathogens from 
polymicrobial communities to adjust their behavior in response to other neighboring 
bacteria and they deserve particular attention. This chapter aims to describe some of the 
mechanisms used by Pseudomonas aeruginosa and Staphylococcus aureus for their mutual 
coexistence and persistence in the host environment, and to emphasize those that are 
potential targets for the development of anti-pathogenesis therapies.  
2. Microbiology of CF 
Colonization of the CF airways by bacteria usually occurs in infancy and results in the 
establishment of chronic infections which eventually lead to respiratory failure and death 
(Harrison, 2007; Lyczak et al., 2002). Recent investigations have shown that the CF airways are 
colonized by complex polymicrobial communities constituted by numerous bacterial species 
and not only by the relatively few predominant species originally described that include P. 
aeruginosa, S. aureus, Heamophilus influenzae, bacteria from the Burkholderia cepacia complex and 
Stenotrophomonas maltophilia (Sibley & Surette, 2011). Notwithstanding this polymicrobial 
mixture, P. aeruginosa and S. aureus are still among the most prevalent and dominant bacterial 
species encountered in CF (Canadian Cystic Fibrosis Foundation, 2009; Cystic Fibrosis 
Foundation, 2009; European Cystic Fibrosis Society, 2007). It is also important to note that the 
prevalence of the different pathogens varies as a function of the age of patients, with S. aureus 
and H. influenzae being more frequent in early childhood and P. aeruginosa being more 
important as patients become older. Several other microorganisms such as Mycobacterium spp., 
pathogenic viruses, fungal pathogens (e.g. Aspergillus fulmigatus) and yeasts (e.g. Candida 
albicans) have also been recovered from the CF airways and may also contribute to disease 
(Harrison, 2007; Lyczak et al., 2002; Moskowitz et al., 2005). It should be kept in mind that the 
chronically infected CF airways represent a complex and diverse ecosystem and that the 
precise contribution of the different microbes to the morbidity of the disease remains 
undetermined, even for the less frequently encountered microorganisms (Harrison, 2007).  
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2.1 Pathogenesis of P. aeruginosa in CF 
P. aeruginosa is a Gram-negative bacterium that has the ability to survive in several 
different natural environments. However, it is better known as an opportunistic 
antibiotic-resistant human pathogen often encountered in hospital settings (Bodey et al., 
1983). This bacterium is also known as the major cause of lung function decline and 
mortality in CF (Lyczak et al., 2002). P. aeruginosa establishes infections using several 
virulence factors. The production of these virulence factors varies as a function of the cell 
density of the bacterial population and is controlled by cell-to-cell chemical 
communication, i.e. quorum-sensing or QS (R. S. Smith & Iglewski, 2003). QS systems are 
used by many bacteria to promote collective behaviors and depend on the action of 
diffusible signal molecules. QS systems are typically composed of a signal synthase that 
produces the signal molecule and a signal receptor that modulates the expression of target 
genes subsequent to the binding of the signal molecule. 
QS in P. aeruginosa is controlled by the las and rhl N-acylhomoserine lactone (AHL) 
regulatory circuits and by the 2-alkyl-4-quinolone (AQ) system (Dubern & Diggle, 2008). 
In the las and rhl system, the lasI and rhlI gene products direct the synthesis of the 
homoserine lactones (HSL) 3-oxo-C12-HSL and C4-HSL, which interact with the 
transcription regulators LasR and RhlR, respectively, and activate target promoters. The 
las and rhl systems are hierarchically connected and interact together to regulate the 
production of several virulence determinants such as pyocyanin biosynthesis and biofilm 
formation (Dubern & Diggle, 2008; R. S. Smith & Iglewski, 2003). The AQ system is also 
interconnected with las and rhl and leads to the production of 2-heptyl-4-quinolone 
(HHQ) and the Pseudomonas quinolone signal (PQS). Both HHQ and PQS also have a role 
in cell-to-cell communication. However, PQS has a number of other biologically 
important functions (Dubern & Diggle, 2008). P. aeruginosa produces several other 
quinolone compounds, some of which, such as 4-hydroxy-2-heptylquinoline-N-oxide 
(HQNO), have antibiotic activity (Leisinger & Margraff, 1979; Lépine et al., 2004; Machan 
et al., 1992). It should also be kept in mind that the control of virulence factors by these 
systems is growth and environment dependent. This complex mixture of factors allows 
P. aeruginosa to modulate its behavior only when necessary (Williams & Camara, 2009). 
Interestingly, P. aeruginosa QS signals not only serve for intraspecies communications, 
but are also known to affect other microorganisms and the host (Williams & Camara, 
2009). The association between the environment, P. aeruginosa QS systems and virulence 
is schematized in Fig. 1. 
Substantial adaptive and genetic changes occur in the genome of P. aeruginosa during 
chronic infections of the CF airways (Foweraker et al., 2005; E. E. Smith et al., 2006; Sriramulu 
et al., 2005). These changes cause bacteria to diversify and to exhibit characteristics differing 
from isolates found in the environment outside the body. The adaptation of P. aeruginosa 
during persistent infection of CF lungs can often lead to antimicrobial resistance, alginate 
overproduction and improved metabolic fitness. Overall, P. aeruginosa seems able to adopt a 
less aggressive profile by repressing its virulence factors and its immunostimulatory 
products, by growing in biofilms and by metabolically adapting to the microaerobic 
environment created by airway mucus plugs (Hogardt & Heesemann, 2010). Of these 
characteristics it appears that the formation of drug-resistant biofilms is strongly associated 
with the persistence of this bacterium in the CF airways (Høiby et al., 2010; Wagner & 
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Iglewski, 2008). Also, non-mucoid strains that colonize CF patients can, with time, switch to 
the mucoid phenotype, show resistance to various antibiotics and become more difficult to 
eradicate from the airways (George et al., 2009). Other phenotypic variants associated with 
chronic infections and antibiotic tolerance have also been recovered from the CF airways 
such as persister cells (Mulcahy et al., 2010) and small-colony variants (Häußler et al., 1999; 
Schneider et al., 2008). The hypermutability of P. aeruginosa CF strains is thought to 
accelerate the development of antibiotic resistances and the adaptation required for long-
term persistence in the host (Maciá et al., 2005).  
 
 
 
 
 
 
 
 
Fig. 1. The virulence of P. aeruginosa is controlled by interconnected quorum-sensing (QS) 
systems that integrate environmental cues and influence virulence gene expression. The two 
N-acylhomoserine lactone systems las and rhl and the 2-alkyl-4-quinolone (AQ) system are 
hierarchically interconnected. The las system is usually activated first. These QS systems 
regulate the production of several virulence factors as a function of growth and in response 
to the environment not only to influence P. aeruginosa behavior but also other bacteria of the 
microbial community as well as host-pathogen interactions.  
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2.2 Pathogenesis of S. aureus in CF  
S. aureus can live as a human commensal but also can be an opportunistic Gram-positive 
pathogen associated with significant mortality in hospitals (Talbot et al., 2006). This 
bacterium demonstrates an impressive versatility being able to infect several hosts, organs 
and body sites and cause both life-threatening and chronic infections (Archer, 1998; Goerke 
& Wolz, 2010). The treatment of S. aureus is seriously impeded by antibiotic resistance that 
has spread among staphylococci and is now being considered as a serious threat to the 
general population (Witte et al., 2008).  
The presence of numerous virulence genes in the genome of S. aureus is thought to 
explain the ability of this bacterium to cause a broad spectrum of diseases (Archer, 1998). 
The genes involved in pathogenesis are tightly controlled by complex regulatory 
networks that allow the bacteria to express its virulence factors as a function of the 
bacterial population density and of its environment (Novick, 2003). One of the most 
characterized regulatory systems influencing the virulence of S. aureus is agr, the 
quorum-sensing accessory gene regulator, that upregulates the production of several 
extracellular proteins while downregulating many cell-surface proteins (Novick & 
Geisinger, 2008). Other regulatory networks that govern the expression of accessory 
genes in S. aureus include several two-component regulatory systems and transcription 
factors such as the alternative sigma factor SigB (Bronner et al., 2004; Novick, 2003). The 
activity of particular virulence regulators is thought to allow the expression of different 
sets of factors likely to be required at specific steps during infection or needed for 
different types of infections.  
The contribution of S. aureus to the progression of disease in CF is less obvious than that 
of P. aeruginosa. Although the presence of this bacterium in the lower respiratory tract is 
considered as representative of a pathologic situation, there are still questions 
concerning the impact of S. aureus on the progression of the disease (Lyczak et al., 2002). 
However, recent data indicate that while the prevalence of P. aeruginosa has declined 
among CF patients over the past few years, the incidence of methicillin-suceptible and 
methicillin-resistant S. aureus (MSSA and MRSA, respectively) has increased in the USA 
(Razvi et al., 2009). Importantly, detection of persistent MRSA in the respiratory tract of 
CF patients has been associated with a decrease in survival and with a more rapid 
decline in lung function (Dasenbrook et al., 2008; Dasenbrook et al., 2010). Furthermore, 
MRSA bacteria often present a phenotype of mutiresistance to antibiotics (Chambers & 
Deleo, 2009; Pruneau et al., 2011) and are proficient in biofilm production (Molina et al., 
2008).   
Notwithstanding these findings, S. aureus often persists in the CF lungs for many months or 
even years and is the cause of recurrent and relapsing infections despite antibiotic 
treatments (Goerke & Wolz, 2010; B. C. Kahl, 2010). Long-term adaptation of S. aureus to the 
CF environment may occur through mutations (such as those causing the small-colony 
variant [SCV] phenotype) or through regulatory mechanisms that are still not well 
understood and that may result in the repression of the agr system and establishment of 
biofilms (Goerke & Wolz, 2010).  
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SCVs of S. aureus are often isolated from chronic infections such as those of the CF airways 
(Kahl et al., 1998; Moisan et al., 2006; Proctor et al., 2006). The SCV phenotype is frequently 
caused by either mutations in genes required for electron transport (e.g. genes involved in 
the biosynthesis of hemin or menadione) or by mutations in genes enabling thymidine 
biosynthesis. Almost all the phenotypic characteristics of SCVs such as the slow growth (i.e., 
the formation of pin-point colonies when grown on solid media), the altered susceptibility to 
aminoglycoside antibiotics and the decreased production of exotoxins can be explained by 
their dysfunctional electron transport (Proctor et al., 2006). Several studies have reported 
that SCVs are less virulent than prototypical strains in vivo yet they can persist as well as the 
normal strains (Proctor et al., 2006). Our group and others have demonstrated that SCVs are 
relatively more persistent than their normal counterparts under antibiotic pressure (Bates et 
al., 2003; Brouillette et al., 2004).  A recent study supports the theory that bacterial switching 
between wild-type and SCV phenotypes is required to sustain chronic infections 
(Tuchscherr et al., 2011).  
The hypothesis that SCVs play a role in the development of chronic infections is well 
supported by in vitro experiments demonstrating that these variants have an increased 
ability to adhere to host tissue components (Mitchell et al., 2008; Vaudaux et al., 2002), to 
form biofilms (Mitchell et al., 2010a, 2010b; Singh et al., 2009, 2010) and to infect and 
persist within non-professional phagocytes (Mitchell et al., 2011b; Sendi & Proctor, 2009). 
These in vitro characteristics can be explained by the impact of the defective electron 
transport chain on the expression of virulence factors which seem to be mostly controlled 
by the activity of SigB rather than by the agr system in SCVs (Moisan et al., 2006; Senn et 
al., 2005). This altered activation of virulence regulators triggers a sustained expression of 
several genes encoding cell-surface proteins (e.g. the fibronectin-binding protein A fnbA 
gene) and the down-regulation of several exoprotein genes (e.g. the hemolysin-ǂ hla gene) 
(Mitchell et al., 2008; Moisan et al., 2006). The sustained expression of fnbA has been 
associated with efficient binding of SCVs to fibronectin (Mitchell et al., 2008). In turn, the 
formation of a fibronectin bridge between S. aureus fibronectin-binding proteins and the 
ǂ5ǃ1-integrin of eukaryotic cells (Sinha et al., 1999) probably explains the proficient 
cellular internalization of SCVs (Sendi & Proctor, 2009). Additionally, the low production 
of exoproteins and toxins by SCVs is likely to account for their increased persistence 
within host cells (Sendi & Proctor, 2009). Moreover, the increased production of biofilm 
by SCVs in comparison with wild-type strains may possibly be explained by the relative 
influence and the interconnection of the agr system and SigB that manipulate the 
maturation of protein-dependent biofilms (Lauderdale et al., 2009). Furthermore, SCVs 
have been shown to activate the innate immune response to a lesser extent than that 
observed with wild-type strains (Tuchscherr et al., 2010). This reduced ability of SCVs to 
induce an inflammatory response may also be attributable to the repression of the agr 
system (Grundmeier et al., 2010) and supports the idea that the SCV phenotype confers on 
S. aureus the ability to remain hidden from the host immune system inside non-
professional phagocytes. However, to date, the in vitro observations that suggest that the 
formation of biofilms and the infection of host cells by SCVs allow S. aureus to establish 
long-term infections in CF patients have not been supported by in vivo experiments. 
Further work is required, especially in CF models of pulmonary infections, in order to 
fully understand the role of SCVs in the pathogenesis of S. aureus. Some of the 
characteristics of the normal and SCV strains are compared in Fig. 2.  
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Fig. 2. The ability to switch from the normal to the small-colony variant (SCV) phenotype 
may have an impact on the virulence of S. aureus. (A) S. aureus can switch from a normal to a 
SCV phenotype. The normal and SCV phenotypes are associated with the dissemination of 
bacteria and acute infections, and with host tissue colonization and persistent infections, 
respectively. In comparison to normal strains, SCVs form pinpoint colonies, are less or non-
hemolytic on blood agar plates and have an increased ability to infect non-professional 
phagocytes and to form biofilms (B). The host-cell infection pictures were prepared as 
previously described (Mitchell et al., 2011a, 2011b) and show Calu-3 cells with actin colored 
in green and internalized S. aureus bacteria in red. Scale bar is 50 μm. Biofilm formation was 
evaluated by crystal violet staining as previously decribed (Mitchell et al., 2010a, 2010b).  
3. Interspecies interactions between CF pathogens 
It is now accepted that bacteria can sense signal molecules across species’ boundaries and 
that this signaling influences the development of microbial communities and the virulence 
and persistence of pathogens during infections (Ryan & Dow, 2008). The clinical impact of 
polymicrobial infections is receiving more and more recognition from the medical 
community. There are indeed several examples of polymicrobial infections where at least 
two different microorganisms influence the course of the disease by synergistic, additive or 
antagonistic effects. Also, biofilms are thought to be of major importance for the 
pathogenesis of bacteria in the context of CF lung infections (Davies & Bilton, 2009) and can 
be considered as integrated and complex polymicrobial communities whose development is 
controlled by interspecies communications (Stoodley et al., 2002). Accordingly, and as 
previously underlined, infections of the CF airways is highly polymicrobic and there is 
growing evidence that many of these microorganisms interact (Sibley & Surette, 2011) as 
observed between P. aeruginosa and S. aureus (Biswas et al., 2009; Hoffman et al., 2006; 
Mashburn et al., 2005; Mitchell et al., 2010b; Qazi et al., 2006; Yang et al., 2011), P. aeruginosa 
and Burkholderia spp. (Bakkal et al., 2010; Chattoraj et al., 2010; Riedel et al., 2001; Weaver & 
Kolter, 2004), P. aeruginosa and S. maltophilia (Ryan et al., 2008), P. aeruginosa and C. albicans 
(McAlester et al., 2008), and more generally with a large proportion of the organisms found 
in the CF airways (Duan et al., 2003; Sibley et al., 2008).  
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3.1 Interactions between P. aeruginosa and S. aureus  
Given that P. aeruginosa and S. aureus are highly prevalent and commonly co-isolated from 
the CF airways (Harrison, 2007; Hoffman et al., 2006), a great deal of effort has been directed 
toward the characterization of the interaction between them. Historically, synergistic 
interactions between these two species have been proposed and it was thought that S. aureus 
could sensitize the lungs for subsequent infections by P. aeruginosa (Lyczak et al., 2002). 
However, it is now clear that antagonistic interactions also exist between these bacteria as P. 
aeruginosa has the ability to provoke lysis of S. aureus cells (Mashburn et al., 2005; Palmer et 
al., 2005). The structures of some P. aeruginosa exoproducts that are known to impact on S. 
aureus are shown in Fig. 3. 
 
Fig. 3. Structure of P. aeruginosa molecules influencing S. aureus viability and pathogenesis.  
The antistaphylococcal activities of pseudomonal HQNO (see Fig. 3) and other 4-hydroxy-2-
alkylquinolines (HAQs) have been known for many years and are molecules that can generally 
suppress the growth of many Gram-positive bacteria (Lightbown & Jackson, 1954; Machan et 
al., 1992). Mashburn et al. (2005) suggested that P. aeruginosa could exploit this property to lyse 
S. aureus cells in order to use the released iron for growth in low-iron environments. 
Interestingly, HQNO also allows some Gram-positive to grow slowly in presence of 
aminoglycoside antibiotics (Lightbown, 1954) and the reason for this has remained a mystery 
for several years. The protection provided by HQNO against the inhibitory activity of 
aminoglycosides was finally found to be related to the ability of this molecule to inhibit the 
Gram-positive electron transport chain (Hoffman et al., 2006), which is required for 
aminoglycoside uptake (Bryan & Van Den Elzen, 1977). It was further shown that prolonged 
exposure of S. aureus to HQNO (or to P. aeruginosa) selects for SCVs (Hoffman et al., 2006). We 
subsequently demonstrated that HQNO produced by P. aeruginosa not only stimulates the 
formation of S. aureus biofilms but also modulates the activity of virulence regulators. More 
particularly, while increasing the activity of SigB and the expression of sarA, HQNO 
downregulates the expression of the effector of the agr system (RNAIII). This modulation of 
regulator activities is likely to influence the expression of several virulence factors as was 
shown for fnbA and hla (Mitchell et al., 2010b). The interaction of PQS with the cell envelope of 
P. aeruginosa is also known to trigger the release of membrane vesicles (MVs) which contain 
toxins, DNA, antimicrobials as well as HHQ, PQS and HQNO. It is thought that MVs are 
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important for the trafficking of PQS within the P aeruginosa population as PQS is poorly 
soluble in water. However, since MVs contain AQs including HQNO, they could also inhibit 
staphylococcal growth (Mashburn & Whiteley, 2005). Furthermore, P. aeruginosa produces 
other small-molecule respiratory inhibitors such as pyocyanin (see Fig. 3) and hydrogen 
cyanide which can affect the respiration of S. aureus (Voggu et al., 2006) and potentially select 
for the SCV phenotype (Biswas et al., 2009). Whether and how these other respiratory 
inhibitors influence the virulence of S. aureus remains to be determined. Fig. 4 shows the effect 
of P. aeruginosa on the growth of S. aureus, the HQNO-mediated emergence of SCVs and the 
stimulation of S. aureus biofilm production by HQNO. 
 
Fig. 4. P. aeruginosa influences the phenotypic switching of S. aureus and may have an impact 
on its virulence. (A) P. aeruginosa promotes the emergence of SCVs from normal S. aureus 
strains through the production of respiratory inhibitors such as HQNO and pyocyanin. Dotted 
arrows indicate other potential interactions between these bacterial species. (B) P. aeruginosa 
inhibits the growth of S. aureus. (C) HQNO stimulates the emergence of SCVs in S. aureus. 
Bacteria were treated or not with 10 μg/ml of HQNO for 18 h and plated on agar containing 
gentamicin at 4 μg/ml to reveal the presence of SCVs. (D) HQNO and P. aeruginosa culture 
supernatants enhance biofilm production by a normal S. aureus strain. S. aureus biofilms were 
produced in the presence of 10 μg/ml of HQNO or in the presence of culture supernatants 
from P. aeruginosa or Escherichia coli (acting as a negative control) and were revealed by crystal 
violet staining as previously described (Mitchell et al., 2010a, 2010b).   
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It also appears that factors other than pseudomonal respiratory inhibitors are involved in 
the microbial interactions occurring between P. aeruginosa and S. aureus. Importantly, 
most of the antistaphylococcal activity found in P. aeruginosa culture supernatant is 
attributed to the staphylolytic endopeptidase LasA (Kessler et al., 1993). Qazi et al. (2006) 
demonstrated that some long-chain 3-oxo-substituted N-acylhomoserine lactones (AHL) 
such as 3-oxo-C12-homoserine lactone (see Fig. 3) can inhibit the growth of S. aureus as a 
function of their concentrations. The 3-oxo-C12-HSL also modulates the production of S. 
aureus exotoxins and cell-surface proteins through the repression of sarA and agr by 
interaction with a specific and saturable receptor(s) at the cytoplasmic membrane. 
Furthermore, the 3-oxo-C12-HSL is capable of undergoing internal re-arrangement to 
form the 3-oxo-C12-tetrameric acid, which also has an inhibitory activity against Gram-
positive bacteria (Kaufmann et al., 2005). A recent study investigated the formation of 
biofilms by P. aeruginosa-S. aureus co-cultures using a flow chamber system and confocal 
microscopy (Yang et al., 2011). This study demonstrated that wild-type P. aeruginosa 
facilitates S. aureus microcolony formation, but that mucA and rpoN mutants do not have 
this property and tend to outcompete S. aureus. A role for type IV pili in this phenomenon 
was proposed to occur through binding of extracellular DNA, and it was demonstrated 
that P. aeruginosa protects S. aureus against Dictyostelium discoideum phagocytosis when in 
co-culture biofilms.  
Some studies have been carried out to substantiate the interactions between P. aeruginosa 
and Staphylococcus epidermidis, a bacterium closely related to S. aureus. It was shown that 
some P. aeruginosa extracellular products (possibly polysaccharides) provide a competitive 
advantage over S. epidermidis (Qin et al., 2009). Furthermore, Pihl et al. (Pihl et al., 2010a, 
2010b) demonstrated that some S. epidermidis strains were better fitted than others to coexist 
in biofilms with P. aeruginosa whereas the ability of P. aeruginosa to inhibit S. epidermidis  
biofilms varied between clinical isolates. These authors suggested that specific P. aeruginosa 
strains might be selected during infections to counteract chronic colonization by S. 
epidermidis in order to allow the persistence and dominance of P. aeruginosa. Whether the 
genetic background of each strain also influences interspecies interactions between S. aureus 
and P. aeruginosa and whether the outcome of these interactions varies in each CF patient 
remains to be determined. Recent studies, which demontrate that P. aeruginosa lasR mutants 
are frequently found in CF, indicate that some of the abilities of this bacterium to influence 
the virulence of S. aureus may indeed be lost during CF lung infections (D'Argenio et al., 
2007; Hoffman et al., 2009).  
Other questions remain open. For example, the real impact of S. aureus-P. aeruginosa co-
infections in CF is not known and convincing clinical data as well as co-infection in 
adequate experimental models are clearly missing. Whether S. aureus and P. aeruginosa have 
a synergistic or antagonistic effect on the progression of the disease is not known and may 
potentially be influenced by the nature of each clinical isolate. Furthermore, whereas the 
effect of P. aeruginosa on S. aureus has been studied widely, almost no investigations address 
the potential effect of S. aureus on the virulence of P. aeruginosa. Interestingly, Korgaonkar 
and Whiteley (2011) proposed a model in which P. aeruginosa senses surrounding bacteria 
by monitoring the presence of exogenous peptidoglycan and responds to it by increasing the 
production of the virulence factor pyocyanin.  
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4. New therapeutic approaches in CF 
Humanity is now facing a post-antibiotic era defined by its limited capability to combat 
microbial infections caused by antibiotic resistant pathogens. The increased number of 
nosocomial and community-acquired infections caused by microorganisms resistant to at 
least two classes of conventional antibiotics is becoming an important public health 
problem. The global rise of antimicrobial resistance combined with the slow discovery and 
approval processes for classical antibiotics has resulted in the present urgent need for new 
and innovative therapeutic approaches. One of the reasons for multidrug resistance is that 
current antibiotics were designed around a limited number of chemical scaffolds with few 
major modifications since the 1980s. This has left plenty of opportunities for antibiotic 
resistance mechanisms to develop and spread worldwide (Shah, 2005; Talbot et al., 2006). 
The identification of new antimicrobial targets and the development of novel therapeutic 
approaches may be facilitated by a better understanding of bacterial pathogenesis both at 
the single species and bacterial community levels. Antibiotic resistant bacteria are often 
recovered from CF patients but recalcitrance to antibiotic therapies is not only caused by 
bacterial genes that encode conventional mechanisms of antibiotic resistance. Indeed, the 
ever changing epidemiology of the CF airways (Razvi et al., 2009) and the acquisition of 
bacterial phenotypes inherently resistant to antimicrobials contribute to treatment failures. 
Although some antibiotics have recently been approved or are close to being approved for 
clinical use and are promising in the context of CF (Parkins & Elborn, 2010), this section will 
talk about some novel therapeutic approaches that take into account the pathogenesis and 
the adaptation of CF pathogens in the context of polymicrobial infections. However, in order 
to appreciate the entirety of the efforts directed toward the cure of CF, it should be kept in 
mind that a number of strategies other than those using antibiotherapies are also being 
considered (George et al., 2009). 
4.1 Modulation of biofilm-forming microbial communities 
The formation of biofilms by CF pathogens is thought to be a major virulence asset that 
promotes resistance both to antimicrobials and the host immune system (Costerton et al., 
1999; Davies & Bilton, 2009; Høiby et al., 2010; Stewart, 2002). This fully justifies current 
research aimed at the development of therapeutic strategies that target biofilm formation 
and dispersal (Simões, 2011). Current management practices for P. aeruginosa infections 
include hygienic measures (Høiby & Pedersen, 1989), early aggressive eradication by 
antimicrobial therapy (Döring & Høiby, 2004), the use of nebulized DNAse (Frederiksen et 
al., 2006) and chronic suppressive antibiotic therapy (Bjarnsholt et al., 2009; Döring et al., 
2000). However, even if these methods are undeniably successful to a certain extent, chronic 
infection ultimately occurs and a gradual increase in the level of resistance is observed 
(Ciofu et al., 1994). New therapeutic approaches specifically targeting biofilms should thus 
be useful in the context of CF lung infections and should decrease the occurrence or 
development of antibiotic resistance. 
Most natural biofilms are polymicrobial (Stoodley et al., 2002) and the polymicrobial nature 
of CF lung infections needs to be considered in novel therapeutic approaches (Sibley et al., 
2009; Sibley & Surette, 2011). Whereas some microbes may predispose the tissue toward the 
colonization by others, there may also be competition among bacterial populations and the 
removal of one pathogen could create an opportunity for another to expand (Harrison, 
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2007). On the other hand, tampering with the CF airway microbial community may lead to 
more effective treatment of chronic infections (Moore et al., 2005). Some data even suggest 
that a healthy gut microflora protects against some respiratory pathogens (Alvarez et al., 
2001; Villena et al., 2005) and that care should be taken not to deplete the gut microflora 
when oral or intravenous routes of antibiotic administration are used. It is also conceivable 
that monitoring the population dynamics of polymicrobial infections can be used to predict 
the efficacy of antimicrobial therapy and to optimize treatments (Rogers et al., 2010). As 
such, the impact of antimicrobial chemotherapies on microbial communities should be 
assessed to detect unwanted effects. As an example, aminoglycosides, which are indicated 
for the management of acute exacerbations, the control of chronic infections and the 
eradication of recently acquired P. aeruginosa, have also been shown to induce bacterial 
biofilms in both P. aeruginosa (Hoffman et al., 2005) and S. aureus (Mitchell et al., 2010a).  
The next sections provide examples of methods by which biofilm infections may be 
potentially overcome using different strategies that include targeting specific microbial 
phenotypes, influencing the pathogenesis of bacteria through the manipulation of cell-to-cell 
signaling and the enhancement of preexisting antimicrobial therapies against persistent 
forms of bacteria.  
4.2 Targeting the persistent microbial phenotype 
Bacteria often encounter unfavorable conditions during infection that limit bacterial growth 
and oblige the microorganisms to enter a quiescent state in order to persist within the host 
(Kolter et al., 1993; Nataro et al., 2000). Dormant bacteria are well-known for their tolerance 
to antibiotics normally active against rapidly dividing cells and often require prolonged 
periods of treatment (Coates et al., 2002; Neu, 1992). The highly refractory nature of biofilms 
to eradication by chemotherapy is thought to be at least partly attributable to the presence of 
metabolically inactive cells (Fux et al., 2005). The inefficacy of antibiotics against non-
multiplying bacteria thus results in slow or partial death, prolonges the duration of therapy 
and increases the emergence of genotypic resistances. Accordingly, targeting slow-growing 
or non-dividing bacteria should provide substancial therapeutic benefits.  
Membrane-acting agents are usually active against bacteria in all their phases of growth and 
are thus good candidates for the development of antimicrobials that target slow-growing 
and non-dividing bacteria. As an example, the novel porphyrin antibacterial agents XF-70 
and XF-73 were shown to remain highly active against this type of bacteria (Ooi et al., 2010). 
Hu et al. (2010) found that the small quinolone-derived compound HT61 was active against 
non-multiplying MSSA and MRSA by causing depolarization of the cell membrane and 
destruction of the cell wall. Antimicrobial peptides also interact and permeabilize the 
bacterial membrane and there is a good probability that they act on slow-growing bacteria 
that form biofilms (Batoni et al., 2011). Bioactive peptides may even have additional benefits 
for CF therapeutic applications due to their anti-inflammatory and immunomodulating 
activities (Scott et al., 2007; Zhang et al., 2005). 
The resistance of biofilms to killing by most antimicrobial agents is thought to be more 
specifically attributable to the presence of non-dividing persister cells (Lewis, 2007). 
Persisters are dormant bacteria that present a global slowdown in metabolic processes, do 
not divide and are tolerant to antibiotics. In other words, they have the ability to survive the 
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effects of antibiotics without the use of drug-specific resistance mechanisms. Persisters have 
been described for S. aureus (Allison et al., 2011; Singh et al., 2009) and P. aeruginosa, with a 
recent study that shows the emergence of strains producing high levels of persister cells in 
CF patients (Mulcahy et al., 2010). Currently, there are only a few therapeutic strategies that 
are considered for targeting persister cells. One such is the combination of conventional 
antibiotics with an inhibitor of an essential persister protein (Lewis, 2007). Also, repeated- or 
pulse-dosing of antibiotics could allow persister cells to resuscitate in order to be killed by 
subsequent antibiotic administration. The development of specific pro-antibiotics which 
could irreversibly bind to bacterial targets is also being considered (Lewis, 2007). An 
outstanding recent study shows that the use of specific metabolic stimuli enables the killing 
of persister cells with aminoglycoside antibiotics by modulating the proton-motive force 
required for the uptake of these drugs. The proof of concept for the latter approach has been 
demonstrated against biofilms and also in a model of chronic infection (Allison et al., 2011).  
As we have previously mentioned, SCVs are often associated with relapsing and persistent 
infections. In addition to the increased ability of these variants to form biofilms (Al Laham et 
al., 2007; Häußler et al., 2003; Mitchell et al., 2010a, 2010b; Singh et al., 2009, 2010; von Götz et 
al., 2004), SCVs are well-known for their ability to infect and persist within non-professional 
phagocytes (Sendi & Proctor, 2009) and there is a limited choice of antibiotics able to act 
against intracellular bacteria. Nguyen et al. (Nguyen et al., 2009a) reported a considerable 
decrease in the efficacy of most antibiotics against intracellular SCVs in comparison to that 
seen against extracellular bacteria, but, most importantly, in comparison to their efficacy 
against the normal-phenotype bacteria. Nevertheless, the authors noted that four antibiotics 
(quinupristin-dalfopristin, moxifloxacin, oritavancin and rifampicin) were more effective in 
killing intracellular SCVs. In addition, we recently described the first known molecule to 
specifically target the SCV phenotype of S. aureus (Mitchell et al., 2011a). Tomatidine (TO) is 
the aglycone form of the plant secondary metabolite tomatine. The structure and the main 
biological activities of TO against S. aureus are presented in Fig. 5A. We found that TO has a 
bacteriostatic activity against SCVs, but not against normal strains. More importantly, we 
showed that TO has the ability to inhibit the replication of SCVs internalized in CF-like 
human airway epithelial cells (Mitchell et al., 2011a). The specificity of the action of TO 
against SCVs was linked to the dysfunctional electron transport chain of these variants. 
Acordingly, HQNO sensitized normal S. aureus strains to TO (see Fig. 5B), which suggests 
that TO may be especially effective in the context where P. aeruginosa and S. aureus co-infect 
a CF patient. Although TO causes a marked inhibition of protein synthesis in bacteria 
showing a dysfunctional electron transport chain, the exact mechanism of action of TO on 
SCVs remains to be elucidated. Other biological activities for TO are discussed below.  
4.3 Targeting virulence 
Another emerging concept in the development of novel therapeutic approaches is the 
possibility to modulate the expression of virulence factors that are thought to be of major 
importance in the establishment of a particular infection. Modulators or blockers of 
pathogenesis are particularly interesting because it is speculated that, since they do not 
inhibit growth or kill bacteria, their use will not yield a strong selective pressure for 
resistance development. In this context, most attention has been directed toward the 
interference of bacterial QS and cell-to-cell signaling to inhibit virulence or biofilm 
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Fig. 5. Biological activities of tomatidine against S. aureus. (A) Tomatidine (TO) is a steroidal 
alkaloid molecule that inhibits both the extracellular and intracellular replication of SCVs, 
represses the expression of several agr-regulated exoproducts and potentiates the 
bactericidal activity of aminoglycoside antibiotics against prototypical S. aureus. (B) TO (8 
μg/ml) inhibits the growth of a normal S. aureus strain in presence of HQNO (20 μg/ml). 
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Bacteria were inoculated at 105-106 CFU/ml and incubated 24 h at 35oC with shaking. (C) TO 
(8μg/ml) inhibits the hemolytic ability of a normal-growing S. aureus strain. (D) TO may be 
used in combination with aminoglycosides (e.g., gentamicin [GEN]) to eradicate a 
population of S. aureus composed of normal and SCV bacteria. Bacteria were inoculated at 
105-106 CFU/ml and incubated 24 h at 35oC with shaking in presence of 4 μg/ml of GEN 
and/or 0.12 μg/ml of TO. The clear test tubes show no bacterial growth. 
formation (Njoroge & Sperandio, 2009; Rasko & Sperandio, 2010). However, although 
targeting the QS systems of P. aeruginosa in CF infections may increase the susceptibility 
of biofilms to clearance by antibiotics (Hentzer et al., 2003), interference with the QS agr 
system of S. aureus may not be a good strategy since it could increase the formation of 
biofilms and increase bacterial persistence (Novick & Geisinger, 2008; Otto, 2004). The 
discovery of compounds that attenuate or abolish the cross talk between the QS systems 
of different bacterial species may be more promising. It remains to be determined whether 
interference with interspecies communications has the potential to decrease the overall 
virulence or the cohesion of polymicrobial communities and more particularly of those 
found in CF.  
Several plant products have been shown to act as “virulence attenuators” of human 
pathogens (González-Lamothe et al., 2009). Virulence attenuators modulate the virulence or 
the ability of the bacterium to adapt to the host environment. This gives a competitive 
advantage to the host immune system. As an example, a garlic extract was shown to 
interfere with the QS of P. aeruginosa, to sensitize its biofilm to tobramycin treatments and to 
improve clearance of bacteria in a pulmonary mouse model (Bjarnsholt et al., 2005; 
Rasmussen et al., 2005). Ginseng extract was also shown to alter the virulence of P. aeruginosa 
by interfering with QS, destroying biofilms, promoting phagocytosis by airway phagocytes 
and by protecting animals from the development of chronic lung infections (Song et al., 
1997a, 1997b, 2010; Wu et al., 2011). Some of our own transcriptional analyses of bacteria 
exposed to plant products have shed light on the effect of TO on the expression of virulence 
factors by normal S. aureus strains (Bouarab et al., 2007). We demonstrated that TO causes a 
repression in the expression of many extracellular toxins and of RNAIII, the effector 
molecule of the agr system, and thus it inhibits the hemolytic activity of S. aureus. We further 
showed that TO inhibits biofilm formation by S. aureus SCVs, probably through the 
induction of bacteriostasis (Mitchell et al., 2009). We suggest that the overall negative effects 
of TO on the virulence and the growth of both normal and SCV S. aureus strains could be 
used in the management of both acute and chronic lung infections in CF patients. Fig. 5C 
shows the inhibitory effect of TO on the hemolytic ability of a normal S. aureus strain. 
Other studies have also promoted the use of virulence factor-based therapies against S. 
aureus. For example, QS autoinducing peptide variants were shown to inhibit heterologous 
agr activation and were proposed as therapeutic agents (Novick & Geisinger, 2008).  Also, a 
blocker of the synthesis of staphyloxanthin, the golden-carotenoid pigment of S. aureus that 
promotes resistance to reactive oxygen species and host neutrophil-based killing, increased 
the susceptibility of S. aureus to killing by human blood and the innate immune clearance in 
a mouse infection model (Liu et al., 2008). Other researchers have attempted to achieve 
virulence attenuation by manipulation of bacterial metabolism (Lan et al., 2010; Zhu et al., 
2009). Another possible approach is to target the bacterial pathways for programmed cell 
death which have been identified in several species (Engelberg-Kulka et al., 2004). 
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4.4 Enhancing preexisting antimicrobial therapies 
The use of synergistic combinations of antimicrobial compounds is an old strategy that 
continues to be tantalizing especially against the polymicrobial populations found in the CF 
airways. Accordingly, Høiby (2011) suggests that the  effectiveness of combination therapies 
should be tested in the context of CF lung infections. Several combinations of old antibiotics 
indeed showed promising synergistic effects in vitro and/or in vivo such as fosfomycin-
tobramycin, tobramycin-colistin and ciprofloxacin-colistin combinations, with the 
ciprofloxacin-colistin combination thought to be efficient even against P. aeruginosa biofilms 
(Høiby, 2011). A large screen of double and triple antibiotic combinations was tested on 
biofilm-grown B. cepacia and P. aeruginosa in order to identify effective antibiotic 
combinations for the treatment of CF patients (Dales et al., 2009). Combinations of antibiotics 
may also be useful in order to improve the efficiency of antimicrobial treatments against 
intracellular SCVs. As an example, some drug combinations that included rifampicin were 
most effective against intracellular S. aureus of both normal and SCV phenotypes. (Baltch et 
al., 2008). Nguyen et al. (2009b) also showed additive or synergistic effects between 
oritavancin, moxifloxacin and rifampicin against intracellular SCVs.  
The combination of antimicrobial agents with non-antibiotic compounds is also an attractive 
approach (George et al., 2009). Several plant products are “antibiotic potentiators” that can act as 
bacterial efflux pump inhibitors, cell wall-acting agents or membrane destabilizing agents to 
provide synergy with conventional antibiotics (González-Lamothe et al., 2009). Interestingly, we 
have recently demonstrated that TO potentiates the bactericidal activity of aminoglycoside 
antibiotics against normal S. aureus strains of diverse clinical origins and antibiotic susceptibility 
patterns (unpublished results). Although the mechanism(s) by which this effect occurs is yet 
unknown, TO may prove useful in combination therapy with aminoglycoside antibiotics in the 
treatment of CF lung infections as exemplified in Fig. 5D. According to Mohtar et al. (Mohtar et 
al., 2009), a vast number of other plant products with antimicrobial activity await discovery. 
5. Conclusion 
Complex polymicrobial communities colonize the CF airways and interspecies interactions 
are likely to play a role in the course of respiratory infections. P. aeruginosa and S. aureus are 
prevalent pathogens often simultaneously found in CF patients and for which microbial 
interactions that modulate virulence are already well documented. In communities and by 
using intraspecies and interspecies cell-to-cell communication, these pathogens have the 
ability to form biofilms and to adopt persistent phenotypes such as persister cells and SCVs. 
These phenotypes confer non-specific resistance to antimicrobials and to the host immune 
system. The development of novel therapeutic approaches that take into account 
polymicrobial communities and the various strategies that bacteria have elaborated to adapt 
and persist within the CF airways should help to eradicate chronic and life-threatening 
infections in CF.  
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